Checkpoint-Inhibitoren – aktuelle Versorgungsstandards und Zukunftstrends

Die Therapie mit Checkpoint-Inhibitoren revolutioniert nach wie vor die Therapielandschaft der Onkologie. Neben der Monotherapie zeigen Checkpoint-Inhibitoren auch als Teil von Kombinationstherapien sehr gute Ansprechraten. Doch nicht nur bei fortgeschrittenen Tumorerkrankungen lässt sich die Prognose zum Teil erheblich verbessern. Auch die (neo-)adjuvante Therapie liefert vielversprechende Daten.

Abstract

Therapy with checkpoint inhibitors still revolutionizes the therapeutical landscape in oncology. Since the first approval of a checkpoint inhibitor for the therapy of malignant melanoma 2011, many other approvals in the field of hematology and oncology followed. Besides monotherapy, a rapidly increasing number of trials is investigating checkpoint inhibitors in different combination therapies for advanced disease. Cumulating evidence suggests checkpoint blockade also as promising option for (neo)-adjuvant treatment. Here we review the different treatment strategies of mono- and combination-therapies. Additionally, important biomarkers for the treatment with checkpoint inhibitors are discussed.

Schlüsselwörter

Immuntherapie - Checkpoint-Inhibitor - Kombinationstherapie - Biomarker

Key words

immunotherapy - checkpoint inhibitor - combination therapy - biomarkers

Publication History

Article published online:
26 August 2021

• Literatur

• 1 Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14: 1014-1022 DOI: 10.1038/ni.2703.
• 2 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264 DOI: 10.1038/nrc3239.
• 3 Schadendorf D, Hodi FS, Robert C. et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33: 1889-1894 DOI: 10.1200/jco.2014.56.2736.
• 4 Luke JJ, Flaherty KT, Ribas A. et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017; 14: 463-482 DOI: 10.1038/nrclinonc.2017.43.
• 5 Murakami S. Durvalumab for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther 2019; 19: 1009-1016 DOI: 10.1080/14737140.2019.1699407.
• 6 Yoneda K, Imanishi N, Ichiki Y. et al. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). J uoeh 2018; 40: 173-189 DOI: 10.7888/juoeh.40.173.
• 7 Howlader N, Forjaz G, Mooradian MJ. et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020; 383: 640-649 DOI: 10.1056/NEJMoa1916623.
• 8 Lopez-Beltran A, Cimadamore A, Blanca A. et al. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel) 2021; 13: 131 DOI: 10.3390/cancers13010131.
• 9 Oualla K, Castelo Branco L, Nouiyakh L. et al. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker. Cancer Control 2021; 28 DOI: 10.1177/10732748211004878.
• 10 Kato K, Cho BC, Takahashi M. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 1506-1517 DOI: 10.1016/s1470-2045(19)30626-6.
• 11 André T, Shiu KK, Kim TW. et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383: 2207-2218 DOI: 10.1056/NEJMoa2017699.
• 12 Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV. et al. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers (Basel) 2019; 11: 1071 DOI: 10.3390/cancers11081071.
• 13 Liu W, Zhang L, Xiu Z. et al. Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer. Onco Targets Ther 2020; 13: 7229-7241 DOI: 10.2147/ott.S255491.
• 14 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121 DOI: 10.1056/NEJMoa1809615.
• 15 Miles DW, Gligorov J, André F. et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology 2020; 31: S1147-S1148 DOI: 10.1016/j.annonc.2020.08.2243.
• 16 Rugo HS, Schmid P, Cescon DW. et al. Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. Cancer Research 2021; 81: GS3-01 DOI: 10.1158/1538-7445.Sabcs20-gs3-01.
• 17 Zander H, Müller-Egert S, Zwiewka M. et al. [Checkpoint inhibitors for cancer therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 1322-1330 DOI: 10.1007/s00103-020-03221-9.
• 18 Paz-Ares L, Ciuleanu TE, Cobo M. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 198-211 DOI: 10.1016/s1470-2045(20)30641-0.
• 19 Fukumura D, Kloepper J, Amoozgar Z. et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 2018; 15: 325-340 DOI: 10.1038/nrclinonc.2018.29.
• 20 Antonia SJ, Villegas A, Daniel D. et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine 2017; 377: 1919-1929 DOI: 10.1056/NEJMoa1709937.
• 21 Antonia SJ, Villegas A, Daniel D. et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New England journal of medicine 2018; DOI: 10.1056/NEJMoa1809697.
• 22 Lee NY, Ferris RL, Psyrri A. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021; 22: 450-462 DOI: 10.1016/s1470-2045(20)30737-3.
• 23 Wei J, Montalvo-Ortiz W, Yu L. et al. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol 2021; 6: eabg0117 DOI: 10.1126/sciimmunol.abg0117.
• 24 Garcia CA, El-Ali A, Rath TJ. et al. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. Journal for immunotherapy of cancer 2018; 6: 83 DOI: 10.1186/s40425-018-0393-z.
• 25 Weber J, Mandala M, Del Vecchio M. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine 2017; 377: 1824-1835 DOI: 10.1056/NEJMoa1709030.
• 26 Kelly RJ, Ajani JA, Kuzdzal J. et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021; 384: 1191-1203 DOI: 10.1056/NEJMoa2032125.
• 27 Blank CU, Rozeman EA, Fanchi LF. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nature medicine 2018; DOI: 10.1038/s41591-018-0198-0.
• 28 Forde PM, Chaft JE, Smith KN. et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine 2018; 378: 1976-1986 DOI: 10.1056/NEJMoa1716078.
• 29 Chalabi M, Fanchi LF, Dijkstra KK. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26: 566-576 DOI: 10.1038/s41591-020-0805-8.
• 30 de Ruiter EJ, Mulder FJ, Koomen BM. et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol 2020; 34: 1125-1132 DOI: 10.1038/s41379-020-0644-7.
• 31 Fabrizio DA, George Jr TJ, Dunne RF. et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of Gastrointestinal Oncology 2018; 9: 610-617 DOI: 10.21037/jgo.2018.05.06.
• 32 Garmezy B, Gheeya JS, Thein KZ. et al. Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. Journal of Clinical Oncology 2020; 38: 3008 DOI: 10.1200/JCO.2020.38.15_suppl.3008.
• 33 Kruger S, Legenstein ML, Rosgen V. et al. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 2017; 6: e1310358 DOI: 10.1080/2162402x.2017.1310358.
• 34 Bratman SV, Yang SYC, Iafolla MAJ. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer 2020; 1: 873-881 DOI: 10.1038/s43018-020-0096-5.
• 35 Zhang Q, Luo J, Wu S. et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov 2020; 10: 1842-1853 DOI: 10.1158/2159-8290.Cd-20-0047.
• 36 Sezer A, Kilickap S, Gümüş M. et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021; 397: 592-604 DOI: 10.1016/s0140-6736(21)00228-2.
• 37 Herbst RS, Giaccone G, de Marinis F. et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med 2020; 383: 1328-1339 DOI: 10.1056/NEJMoa1917346.
• 38 Powles T, Park SH, Voog E. et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2020; 383: 1218-1230 DOI: 10.1056/NEJMoa2002788.
• 39 Stratigos AJ, Sekulic A, Peris K. et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 848-857 DOI: 10.1016/s1470-2045(21)00126-1.
• 40 Kato K, Shah MA, Enzinger P. et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol 2019; 15: 1057-1066 DOI: 10.2217/fon-2018-0609.
• 41 André T, Lonardi S, Wong K. et al. SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Annals of Oncology 2021; 32: S213-S214 DOI: 10.1016/j.annonc.2021.05.051.
• 42 Baas P, Scherpereel A, Nowak AK. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397: 375-386 DOI: 10.1016/s0140-6736(20)32714-8.
• 43 Choueiri TK, Powles T, Burotto M. et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021; 384: 829-841 DOI: 10.1056/NEJMoa2026982.